Crescent Biopharma, Inc. (CBIO) on GreekSoup https://greeksoup.ai/stocks/us/cbio/ Every dated entry in the public record on Crescent Biopharma, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Fri, 30 Oct 2026 00:00:00 +0000 Crescent Biopharma, Inc.: Schedule 13G filed by BlackRock, Inc., 5.6% of the classhttps://greeksoup.ai/stocks/us/cbio/holders/us:CBIO:schedule-13:2026-10-27:b8195dcd26Tue, 27 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/cbio/filings/us:CBIO:filing:2026-10-15:927677d7e6Thu, 15 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: short interest 4,419,185 shares at the 15 October 2026 settlement, 12.66 days to coverhttps://greeksoup.ai/stocks/us/cbio/short-interest/us:CBIO:short-interest:2026-10-15:205d041574Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: short interest 4,777,172 shares at the 30 September 2026 settlement, 6.85 days to coverhttps://greeksoup.ai/stocks/us/cbio/short-interest/us:CBIO:short-interest:2026-09-30:9c47f1aa99Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc. filed S-8: s-8https://greeksoup.ai/stocks/us/cbio/filings/us:CBIO:filing:2026-09-18:df06e4cd5fFri, 18 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Brumm Joshua T (Chief Executive Officer) sold 7,837 shares (under a trading plan set in advance) at $16.71 on 18 September 2026, $130,956https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:541cb7f624Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Mcneill Jonathan (President and COO) sold 3,839 shares (under a trading plan set in advance) at $16.71 on 18 September 2026, $64,150https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:708c0d9254Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Lynch Ryan (See Remarks) sold 240 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $4,296https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:efcfdefa13Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Pinkas Jan (Chief Scientific Officer) sold 658 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $11,778https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:01cddb4e1bFri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Im Ellie Eunkyung (Chief Medical Officer) sold 623 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $11,152https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:8642fea39cFri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Scalzo Richard William (Chief Financial Officer) sold 568 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $10,167https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:0c453bd373Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Bispham Barbara Harlin (See Remarks) sold 620 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $11,098https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:1d2f254918Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Brumm Joshua T (Chief Executive Officer) sold 1,610 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $28,819https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:07f2958aa5Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Mcneill Jonathan (President and COO) sold 731 shares (under a trading plan set in advance) at $17.90 on 16 September 2026, $13,085https://greeksoup.ai/stocks/us/cbio/insiders/us:CBIO:insider:2026-09-18:cc4c22b46cFri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Form 144, Jonathan McNeill plans to sell 4,415 shares worth $75,850 around 18 September 2026https://greeksoup.ai/stocks/us/cbio/planned-sales/us:CBIO:planned-sale:2026-09-17:99234b90c3Thu, 17 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Form 144, Joshua T Brumm plans to sell 9,013 shares worth $154,843 around 18 September 2026https://greeksoup.ai/stocks/us/cbio/planned-sales/us:CBIO:planned-sale:2026-09-17:9df169a96bThu, 17 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Form 144, Jonathan McNeill plans to sell 804 shares worth $15,115 around 16 September 2026https://greeksoup.ai/stocks/us/cbio/planned-sales/us:CBIO:planned-sale:2026-09-16:20741c5eb2Wed, 16 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Form 144, Joshua T Brumm plans to sell 1,771 shares worth $33,295 around 16 September 2026https://greeksoup.ai/stocks/us/cbio/planned-sales/us:CBIO:planned-sale:2026-09-16:d3cdeb03b0Wed, 16 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: short interest 3,407,158 shares at the 15 September 2026 settlement, 8.51 days to coverhttps://greeksoup.ai/stocks/us/cbio/short-interest/us:CBIO:short-interest:2026-09-15:3f6fe9b996Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: short interest 3,172,374 shares at the 31 August 2026 settlement, 19.91 days to coverhttps://greeksoup.ai/stocks/us/cbio/short-interest/us:CBIO:short-interest:2026-08-31:4d5a0037b1Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: Schedule 13G/A filed by BALYASNY ASSET MANAGEMENT L.P., 6.0% of the classhttps://greeksoup.ai/stocks/us/cbio/holders/us:CBIO:schedule-13:2026-08-14:340afe3231Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Crescent Biopharma, Inc.: short interest 3,216,698 shares at the 14 August 2026 settlement, 17.13 days to coverhttps://greeksoup.ai/stocks/us/cbio/short-interest/us:CBIO:short-interest:2026-08-14:83e57bf1a3Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>